Suppr超能文献

“天然”并不等同于“安全”:天然产物单独和与药物制剂联合的毒性。

"Natural" is not synonymous with "Safe": Toxicity of natural products alone and in combination with pharmaceutical agents.

机构信息

Department of Neurology, University of Alabama at Birmingham, United States.

National Center for Toxicological Research, United States Food and Drug Administration, United States.

出版信息

Regul Toxicol Pharmacol. 2020 Jun;113:104642. doi: 10.1016/j.yrtph.2020.104642. Epub 2020 Mar 18.

Abstract

During the 25 years since the US Congress passed the Dietary Supplement Health and Education Act (DSHEA), the law that transformed the US Food and Drug Administration's (FDA's) authority to regulate dietary supplements, the dietary supplement market has grown exponentially. Retail sales of herbal products, a subcategory of dietary supplements, have increased 83% from 2008 to 2018 ($4.8 to $8.8 billion USD). Although consumers often equate "natural" with "safe", it is well recognized by scientists that constituents in these natural products (NPs) can result in toxicity. Additionally, when NPs are co-consumed with pharmaceutical agents, the precipitant NP can alter drug disposition and drug delivery, thereby enhancing or reducing the therapeutic effect of the object drug(s). With the widespread use of NPs, these effects can be underappreciated. We present a summary of a symposium presented at the Annual Meeting of the Society of Toxicology 2019 (12 March 2019) that discussed potential toxicities of NPs alone and in combination with drugs.

摘要

自 25 年前美国国会通过《膳食补充剂健康与教育法案》(DSHEA)以来,改变了美国食品和药物管理局(FDA)监管膳食补充剂的权力,膳食补充剂市场呈指数级增长。草药产品(膳食补充剂的一个亚类)的零售额从 2008 年到 2018 年增长了 83%(从 48 亿美元增至 88 亿美元)。尽管消费者通常将“天然”与“安全”等同起来,但科学家们深知这些天然产品(NPs)中的成分可能会导致毒性。此外,当 NPs 与药物同时服用时,引发毒性的 NP 会改变药物的处置和药物传递,从而增强或降低目标药物的治疗效果。随着 NPs 的广泛使用,这些影响可能被低估了。我们总结了 2019 年毒理学学会年会(2019 年 3 月 12 日)上的一个专题研讨会,该研讨会讨论了 NPs 单独使用和与药物联合使用的潜在毒性。

相似文献

1
"Natural" is not synonymous with "Safe": Toxicity of natural products alone and in combination with pharmaceutical agents.
Regul Toxicol Pharmacol. 2020 Jun;113:104642. doi: 10.1016/j.yrtph.2020.104642. Epub 2020 Mar 18.
2
FDA regulation of dietary supplements and requirements regarding adverse event reporting.
Clin Pharmacol Ther. 2010 Feb;87(2):239-44. doi: 10.1038/clpt.2009.263. Epub 2009 Dec 23.
5
Twenty Years of the Dietary Supplement Health and Education Act--How Should Dietary Supplements Be Regulated?
J Nutr. 2015 Aug;145(8):1683-6. doi: 10.3945/jn.115.211102. Epub 2015 Jun 10.
6
Marketing dietary supplements in the United States: a review of the requirements for new dietary ingredients.
Toxicology. 2006 Apr 3;221(1):4-8. doi: 10.1016/j.tox.2006.01.010. Epub 2006 Feb 21.
7
The importance of GRAS to the functional food and nutraceutical industries.
Toxicology. 2006 Apr 3;221(1):17-27. doi: 10.1016/j.tox.2006.01.012. Epub 2006 Feb 17.
9
Dietary supplements: What's in a name? What's in the bottle?
Drug Test Anal. 2016 Mar-Apr;8(3-4):410-2. doi: 10.1002/dta.1855. Epub 2015 Nov 2.

引用本文的文献

1
Pharmacological mechanism of natural products to treat osteoporosis: a focus on the autophagy.
Front Pharmacol. 2025 Aug 1;16:1623990. doi: 10.3389/fphar.2025.1623990. eCollection 2025.
2
Vascular and Glycemic Modulation by , an Orchid Used as Traditional Medicine.
Pharmaceuticals (Basel). 2025 Jun 12;18(6):881. doi: 10.3390/ph18060881.
4
Plant antibacterials: The challenges and opportunities.
Heliyon. 2024 May 11;10(10):e31145. doi: 10.1016/j.heliyon.2024.e31145. eCollection 2024 May 30.
5
The mechanisms of natural products for eye disorders by targeting mitochondrial dysfunction.
Front Pharmacol. 2024 Apr 25;15:1270073. doi: 10.3389/fphar.2024.1270073. eCollection 2024.
8
Improving the rigor and utility of botanical toxicity studies: Recommended resources.
Regul Toxicol Pharmacol. 2023 Oct;144:105471. doi: 10.1016/j.yrtph.2023.105471. Epub 2023 Aug 19.
9
Natural STAT3 Inhibitors for Cancer Treatment: A Comprehensive Literature Review.
Recent Pat Anticancer Drug Discov. 2024;19(4):403-502. doi: 10.2174/1574892818666230803100554.

本文引用的文献

1
A marijuana-drug interaction primer: Precipitants, pharmacology, and pharmacokinetics.
Pharmacol Ther. 2019 Sep;201:25-38. doi: 10.1016/j.pharmthera.2019.05.001. Epub 2019 May 7.
3
Cannabis for the Treatment of Epilepsy: an Update.
Curr Neurol Neurosci Rep. 2018 Sep 8;18(11):73. doi: 10.1007/s11910-018-0882-y.
5
"Green Medicine": The Past, Present, and Future of Botanicals.
Clin Pharmacol Ther. 2018 Sep;104(3):410-415. doi: 10.1002/cpt.1168.
7
Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome.
N Engl J Med. 2018 May 17;378(20):1888-1897. doi: 10.1056/NEJMoa1714631.
8
Recommended Approaches for Pharmacokinetic Natural Product-Drug Interaction Research: a NaPDI Center Commentary.
Drug Metab Dispos. 2018 Jul;46(7):1041-1045. doi: 10.1124/dmd.117.079962. Epub 2018 May 7.
10
Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome.
Neurology. 2018 Apr 3;90(14):e1204-e1211. doi: 10.1212/WNL.0000000000005254. Epub 2018 Mar 14.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验